Variant report
Variant | nsv550958 |
---|---|
Chromosome Location | chr10:56236731-56271258 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:32)
- CpG islands (count:0)
- Chromatin interactive region (count:4)
- LncRNA region (count:2)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
(count:32 , 50 per page) page:
1
No data |
(count:4 , 50 per page) page:
1
No. | Distal block | Cell Line | Cell type | Cell Stage |
---|---|---|---|---|
1 | chr10:56255140..56257501-chr10:56263291..56266087,2 | K562 | blood: | |
2 | chr10:56242648..56244262-chr10:56246298..56248916,2 | MCF-7 | breast: | |
3 | chr10:56255140..56257501-chr10:56263291..56266087,2 | K562 | blood: | |
4 | chr10:56242648..56244262-chr10:56246298..56248916,2 | MCF-7 | breast: |
(count:2 , 50 per page) page:
1
No. | lncRNA name | Chromosome Location | lncRNA alias |
---|---|---|---|
1 | lnc-MTRNR2L5-4 | chr10:56245990-56246076 | NONHSAT013457 |
2 | lnc-MTRNR2L5-4 | chr10:56245990-56246076 | ENSG00000234173.1 |
No data |
No data |
Variant related genes | Relation type |
---|---|
ENSG00000234173 | TF binding region |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs12221407 | chr10:56236731-56236732 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
2 | rs183102237 | chr10:56236736-56236737 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs571053471 | chr10:56236763-56236764 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs540064114 | chr10:56236816-56236817 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs57744288 | chr10:56236839-56236840 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs377159422 | chr10:56236845-56236846 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs556297673 | chr10:56236884-56236885 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs575734946 | chr10:56236915-56236916 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs535146888 | chr10:56236921-56236922 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs77137582 | chr10:56236971-56236972 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs376135928 | chr10:56237038-56237039 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs555710978 | chr10:56237095-56237096 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs571741366 | chr10:56237122-56237123 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
14 | rs374420421 | chr10:56237128-56237129 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
15 | rs540644823 | chr10:56237193-56237194 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs76899766 | chr10:56237214-56237215 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs16906167 | chr10:56237320-56237321 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
18 | rs150825002 | chr10:56237337-56237338 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
19 | rs12261810 | chr10:56237438-56237439 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
20 | rs531859771 | chr10:56237439-56237440 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs542376949 | chr10:56237442-56237443 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs562144214 | chr10:56237460-56237461 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs11004330 | chr10:56237467-56237468 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
24 | rs547465699 | chr10:56237506-56237507 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
25 | rs138119237 | chr10:56237512-56237513 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
26 | rs187824401 | chr10:56237513-56237514 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
27 | rs549982830 | chr10:56237536-56237537 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
28 | rs191177223 | chr10:56237549-56237550 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
29 | rs535634422 | chr10:56237598-56237599 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
30 | rs555069612 | chr10:56237606-56237607 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs149598487 | chr10:56237613-56237614 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs11004331 | chr10:56237639-56237640 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
33 | rs373445512 | chr10:56237653-56237654 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs144283231 | chr10:56237707-56237708 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs140544272 | chr10:56237734-56237735 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
36 | rs577893498 | chr10:56237820-56237821 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
37 | rs543318931 | chr10:56237826-56237827 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
38 | rs557277625 | chr10:56237858-56237859 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
39 | rs573911113 | chr10:56237859-56237860 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
40 | rs113131262 | chr10:56237960-56237961 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
41 | rs562203610 | chr10:56237973-56237974 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
42 | rs376983736 | chr10:56237977-56237978 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
43 | rs575594116 | chr10:56238008-56238009 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
44 | rs182953422 | chr10:56238024-56238025 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
45 | rs541419110 | chr10:56238084-56238085 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
46 | rs368589217 | chr10:56238101-56238102 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
47 | rs564294316 | chr10:56238125-56238126 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
48 | rs187911113 | chr10:56238230-56238231 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
49 | rs192987495 | chr10:56238255-56238256 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
50 | rs73255951 | chr10:56238257-56238258 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Pancreatic endocrine tumor | 17639061 | CNVD |
Gastric cancer | 17908304 | CNVD |
Chordoma | 21602918 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Melanoma | 18172304 | CNVD |
Pleomorphic xanthoastrocytoma | 20730472 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Acute lymphoblastic leukemia | 20724749 | CNVD |
Autism | 22495311 | CNVD |
Esophageal cancer | 21851588 | CNVD |
Prostate cancer | 18632612 | CNVD |
Autism | 18414403 | CNVD |
Cockayne syndrome | 18421352 | CNVD |
Glioblastoma | 16823260 | CNVD |
Medulloblastoma | 16968546 | CNVD |
Neuroblastoma | 17533364 | CNVD |
T-cell lymphomas | 19863542 | CNVD |
Testicular germ cell tumor | 18059402 | CNVD |
Squamous cell cancer | 21044232 | CNVD |
Glioma | 21971842 | CNVD |
Cancer | 21637783 | CNVD |
Non-small cell lung cancer | 21044232 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Colorectal cancer | 20709793 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Liposarcoma | 21253554 | CNVD |
Oligodendroglial tumors | 17285580 | CNVD |
Obesity | 21956041 | CNVD |
Developmental delay | 21948486 | CNVD |
Intellectual disability | 21948486 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Lung cancer | 18438408 | CNVD |
Breast cancer | 21364760 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Colorectal cancer | 16272173 | CNVD |
Metanephric adenoma | 20802469 | CNVD |
Autism | 20841430 | CNVD |
Mental retardation | 17124404 | CNVD |
Epilepsy | 20923578 | CNVD |
Prostate cancer | 16573809 | CNVD |
Schizophrenia | 19329560 | CNVD |
Heart failure | 18772530 | CNVD |
Heart failure | 18854381 | CNVD |
Hyperglycemia | 19060297 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Acute lymphoblastic leukemia | 21390130 | CNVD |
Glioblastoma multiforme | 22286061 | CNVD |
Myeloproliferative neoplasm | 20015882 | CNVD |
Usher syndrome | 20538994 | CNVD |
Glioblastoma multiforme | 17002787 | CNVD |
Colorectal cancer | 16774939 | CNVD |
Autism | 20858243 | CNVD |
Breast cancer | 22522925 | CNVD |
Usher type I cohort | 17277737 | CNVD |
Usher type I cohort | 21436283 | CNVD |
Leukemia | 21357790 | CNVD |
Medulloblastoma | 22832581 | CNVD |
Melanoma | 17363583 | CNVD |
Bipolar disorder | 19114987 | CNVD |
Cancer | 20164919 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr10:56234400-56237200 | Weak transcription | HUES64 Cell Line | embryonic stem cell |
2 | chr10:56234400-56237800 | Weak transcription | HUES48 Cell Line | embryonic stem cell |
3 | chr10:56234400-56238200 | Weak transcription | HUES6 Cell Line | embryonic stem cell |
4 | chr10:56234600-56238400 | Weak transcription | iPS-20b Cell Line | embryonic stem cell |
5 | chr10:56234800-56237800 | Weak transcription | iPS-15b Cell Line | embryonic stem cell |
6 | chr10:56236600-56238800 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
7 | chr10:56237200-56238800 | Enhancers | HUES64 Cell Line | embryonic stem cell |
8 | chr10:56237800-56238800 | Enhancers | HUES48 Cell Line | embryonic stem cell |
9 | chr10:56237800-56238800 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
10 | chr10:56238200-56238400 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
11 | chr10:56238200-56238600 | Enhancers | HUES6 Cell Line | embryonic stem cell |
12 | chr10:56238200-56238800 | Enhancers | Brain Germinal Matrix | brain |
13 | chr10:56238400-56238600 | Enhancers | iPS-20b Cell Line | embryonic stem cell |
14 | chr10:56238400-56238800 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
15 | chr10:56240000-56240200 | Enhancers | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
16 | chr10:56243600-56244200 | Enhancers | Breast Myoepithelial Primary Cells | Breast |
17 | chr10:56244200-56245400 | Weak transcription | Breast Myoepithelial Primary Cells | Breast |
18 | chr10:56245800-56246000 | Enhancers | Breast Myoepithelial Primary Cells | Breast |
19 | chr10:56256600-56257000 | Enhancers | Spleen | Spleen |
20 | chr10:56262000-56262400 | Enhancers | hESC Derived CD56+ Mesoderm Cultured Cells | ES cell derived |